• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Adoptive Cellular Therapy Targeting Recurrent Pediatric Brain Cancers During Hematopoietic Recovery from High-Dose Chemotherapy
【24h】

Adoptive Cellular Therapy Targeting Recurrent Pediatric Brain Cancers During Hematopoietic Recovery from High-Dose Chemotherapy

机译：针对复发性小儿脑癌的过继性细胞疗法在大剂量化疗的造血恢复过程中

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A phase I/II clinical trial evaluating the feasibility, safety, and clinical efficacy of adoptive cellular therapy combined with dendritic cell (DC) vaccination targeting recurrent medulloblastoma and PNETs was opened for enrollment at Duke University Medical Center during the previous funding period (Year 1). DC generation and T cell expansion from archived post-induction chemotherapy specimens from five patients with medulloblastoma was attempted and mature RNA-pulsed DCs were successfully generated from 3 of 5 specimens and successful T cell expansion was achieved from these samples. Limitations in the yield of DCs and T cells from these specimens prompted a modification to the protocol to collect a leukapheresis sample prior to induction chemotherapy. A web-based clinical database for patient and laboratory data storage (Oracle Clinical) has been created by the Duke Comprehensive Cancer Center Bioinformatics team and is undergoing final beta testing and personnel training for release. Advertising efforts have increased awareness and recent referrals to the study protocol. Two subjects have been enrolled on the protocol, one removed due to final pathology other than medulloblastoma/PNET, and the other scheduled for surgical resection next week. Two additional subjects are currently undergoing screening for enrollment.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号